Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.19.3.a.u2
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating Expenses    
Research and development expenses $ 2,320,573 $ 3,085,317
General and administrative expenses 1,614,909 1,439,623
Operating Loss (3,935,482) (4,524,940)
Other Income (Expense)    
Interest expense (36,658) (161,205)
Interest income 11,548 18,297
Net Operating Loss Before Income Tax Benefit (3,960,592) (4,667,848)
Income Tax Benefit 602,716 902,801
Net Loss $ (3,357,876) $ (3,765,047)
Net Loss Per Common Share - Basic and Diluted $ (0.70) $ (0.71)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted 5,525,635 5,332,141